{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T18:04:23Z","timestamp":1790359463818,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T00:00:00Z","timestamp":1790294400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04551-x","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:57:54Z","timestamp":1790359074000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Immunochemotherapy response and its association with gut microbiota and immune profiles in advanced gastric cancer"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-9652-6704","authenticated-orcid":false,"given":"XiaoYan","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ChunHong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"WeiXuan","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JunWei","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZhiRong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LiFeng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaQi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,25]]},"reference":[{"issue":"16","key":"4551_CR1","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.3748\/wjg.v29.i16.2452","volume":"29","author":"WJ Yang","year":"2023","unstructured":"Yang WJ, Zhao HP, Yu Y, Wang JH, Guo L, Liu JY, et al. Updates on global epidemiology, risk and prognostic factors of gastric cancer. World J Gastroenterol. 2023;29(16):2452\u201368.","journal-title":"World J Gastroenterol"},{"issue":"10294","key":"4551_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27\u201340.","journal-title":"Lancet"},{"issue":"12","key":"4551_CR3","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2217\/fon-2020-0829","volume":"17","author":"Z Zeng","year":"2021","unstructured":"Zeng Z, Yang B, Liao Z. Progress and prospects of immune checkpoint inhibitors in advanced gastric cancer. Future Oncol. 2021;17(12):1553\u201369.","journal-title":"Future Oncol"},{"issue":"22","key":"4551_CR4","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.2217\/fon-2021-0176","volume":"17","author":"J Tabernero","year":"2021","unstructured":"Tabernero J, Bang YJ, Van Cutsem E, Fuchs CS, Janjigian YY, Bhagia P, et al. KEYNOTE-859: a phase III study of pembrolizumab plus chemotherapy in gastric\/gastroesophageal junction adenocarcinoma. Future Oncol. 2021;17(22):2847\u201355.","journal-title":"Future Oncol"},{"issue":"4","key":"4551_CR5","doi-asserted-by":"publisher","first-page":"290","DOI":"10.21037\/atm-20-6639","volume":"9","author":"S Pan","year":"2021","unstructured":"Pan S, Li K, Huang B, Huang J, Xu H, Zhu Z. Efficacy and safety of immune checkpoint inhibitors in gastric cancer: a network meta-analysis of well-designed randomized controlled trials. Ann Transl Med. 2021;9(4):290.","journal-title":"Ann Transl Med"},{"issue":"9","key":"4551_CR6","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.12669\/pjms.40.9.9049","volume":"40","author":"D Yang","year":"2024","unstructured":"Yang D, Gao Z, Yang X, Gao L. Clinical efficacy and safety of targeted therapy, immunotherapy combined with chemotherapy for treating patients with advanced gastric cancer. Pak J Med Sci. 2024;40(9):2101\u20136.","journal-title":"Pak J Med Sci"},{"issue":"4","key":"4551_CR7","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.21037\/jgo-24-336","volume":"15","author":"W Liu","year":"2024","unstructured":"Liu W, Wang H, Zhao Y, Ge Y, Tang J, Cao M, et al. Efficacy and safety of camrelizumab combined with chemotherapy in the first-line treatment of advanced gastric cancer: a single-arm, phase II study. J Gastrointest Oncol. 2024;15(4):1399\u2013408.","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"4551_CR8","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s11427-024-2831-x","volume":"68","author":"R Zhang","year":"2025","unstructured":"Zhang R, Zhang X, Lau HCH, Yu J. Gut microbiota in cancer initiation, development and therapy. Sci China Life Sci. 2025;68(5):1283\u2013308.","journal-title":"Sci China Life Sci"},{"key":"4551_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111444","volume":"138","author":"JY Xu","year":"2021","unstructured":"Xu JY, Liu MT, Tao T, Zhu X, Fei FQ. The role of gut microbiota in tumorigenesis and treatment. Biomed Pharmacother. 2021;138:111444.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"4551_CR10","doi-asserted-by":"publisher","first-page":"356","DOI":"10.14348\/molcells.2021.0032","volume":"44","author":"J Kim","year":"2021","unstructured":"Kim J, Lee HK. The role of gut microbiota in modulating tumor growth and anticancer agent efficacy. Mol Cells. 2021;44(5):356\u201362.","journal-title":"Mol Cells"},{"key":"4551_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.945887","volume":"13","author":"X Xu","year":"2022","unstructured":"Xu X, Ying J. Gut microbiota and immunotherapy. Front Microbiol. 2022;13:945887.","journal-title":"Front Microbiol"},{"key":"4551_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2147\/CMAR.S503171","volume":"17","author":"R Cao","year":"2025","unstructured":"Cao R, Jiao P, Zhang S, Li J, Liu Q. Predicting the efficacy of immune checkpoint inhibitors in esophageal cancer: changes in peripheral blood lymphocyte subsets before and after immunotherapy. Cancer Manag Res. 2025;17:815\u201325.","journal-title":"Cancer Manag Res"},{"key":"4551_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.912180","volume":"13","author":"K Miao","year":"2022","unstructured":"Miao K, Zhang X, Wang H, Si X, Ni J, Zhong W, et al. Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non-small cell lung cancer. Front Immunol. 2022;13:912180.","journal-title":"Front Immunol"},{"issue":"1","key":"4551_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001460","volume":"9","author":"X Liu","year":"2021","unstructured":"Liu X, Hogg GD, DeNardo DG. Rethinking immune checkpoint blockade: \u201cbeyond the T cell.\u201d J Immunother Cancer. 2021;9(1):e001460.","journal-title":"J Immunother Cancer"},{"key":"4551_CR15","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8536554","author":"X You","year":"2022","unstructured":"You X, Hou FY. Clinical efficacy of image-guided radiation therapy for cervical cancer and its impact on patients\u2019 serum tumor markers and KPS scores. J Oncol. 2022. https:\/\/doi.org\/10.1155\/2022\/8536554.","journal-title":"J Oncol"},{"issue":"5","key":"4551_CR16","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10120-016-0681-6","volume":"20","author":"V Fanotto","year":"2017","unstructured":"Fanotto V, Cordio S, Pasquini G, Fontanella C, Rimassa L, Leone F, et al. Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world. Gastric Cancer. 2017;20(5):825\u201333.","journal-title":"Gastric Cancer"},{"issue":"8","key":"4551_CR17","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/s41416-021-01425-7","volume":"125","author":"MA Baxter","year":"2021","unstructured":"Baxter MA, Middleton F, Cagney HP, Petty RD. Resistance to immune checkpoint inhibitors in advanced gastro-oesophageal cancers. Br J Cancer. 2021;125(8):1068\u201379.","journal-title":"Br J Cancer"},{"key":"4551_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1566939","volume":"16","author":"W Pu","year":"2025","unstructured":"Pu W, Li S, Zhang J, Huang J, Li J, Jiang Y, et al. The efficacy and safety of PD-1\/PD-L1 inhibitors in combination with chemotherapy as a first-line treatment for unresectable, locally advanced, HER2-negative gastric or gastroesophageal junction cancer: a meta-analysis of randomized controlled trials. Front Immunol. 2025;16:1566939.","journal-title":"Front Immunol"},{"key":"4551_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-078876","volume":"385","author":"MZ Qiu","year":"2024","unstructured":"Qiu MZ, Oh DY, Kato K, Arkenau T, Tabernero J, Correa MC, et al. Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial. BMJ. 2024;385:e078876.","journal-title":"BMJ"},{"issue":"1","key":"4551_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-14409-x","volume":"15","author":"H Wu","year":"2025","unstructured":"Wu H, Fan PW, Feng YN, Chang C, Gui T, Meng JB, et al. Role of T cell exhaustion and tissue-resident memory T cells in the expression and prognosis of colorectal cancer. Sci Rep. 2025;15(1):28503.","journal-title":"Sci Rep"},{"key":"4551_CR21","doi-asserted-by":"publisher","first-page":"4193","DOI":"10.2147\/CMAR.S251814","volume":"12","author":"QK Yang","year":"2020","unstructured":"Yang QK, Su YN, Wang W, Wang N, Yao ZX, Zhang XJ. CONUT score or\/and peripheral blood CD4+\/CD8+ ratio-based web dynamic nomograms to predict the individualized survival of patients with advanced osteosarcoma. Cancer Manag Res. 2020;12:4193\u2013208.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"4551_CR22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41379-018-0142-3","volume":"32","author":"H Kim","year":"2019","unstructured":"Kim H, Kwon HJ, Han YB, Park SY, Kim ES, Kim SH, et al. Increased CD3+ T cells with a low FOXP3+\/CD8+ T cell ratio can predict anti-PD-1 therapeutic response in non-small cell lung cancer patients. Mod Pathol. 2019;32(3):367\u201375.","journal-title":"Mod Pathol"},{"issue":"12","key":"4551_CR23","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1007\/s00262-020-02642-4","volume":"69","author":"F Zhang","year":"2020","unstructured":"Zhang F, Bai H, Gao R, Fei K, Duan J, Zhang Z, et al. Dynamics of peripheral T cell clones during PD-1 blockade in non-small cell lung cancer. Cancer Immunol Immunother. 2020;69(12):2599\u2013611.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"4551_CR24","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1158\/2326-6066.CIR-19-0574","volume":"8","author":"H Kagamu","year":"2020","unstructured":"Kagamu H, Kitano S, Yamaguchi O, Yoshimura K, Horimoto K, Kitazawa M, et al. CD4(+) T-cell immunity in the peripheral blood correlates with response to anti-PD-1 therapy. Cancer Immunol Res. 2020;8(3):334\u201344.","journal-title":"Cancer Immunol Res"},{"key":"4551_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2020.100870","volume":"80","author":"S Sivori","year":"2021","unstructured":"Sivori S, Pende D, Quatrini L, Pietra G, Della Chiesa M, Vacca P, et al. NK cells and ILCs in tumor immunotherapy. Mol Aspects Med. 2021;80:100870.","journal-title":"Mol Aspects Med"},{"key":"4551_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.720842","volume":"11","author":"X Liu","year":"2021","unstructured":"Liu X, Cheng Y, Zang D, Zhang M, Li X, Liu D, et al. The role of gut microbiota in lung cancer: from carcinogenesis to immunotherapy. Front Oncol. 2021;11:720842.","journal-title":"Front Oncol"},{"issue":"7","key":"4551_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1312","volume":"13","author":"Z Han","year":"2023","unstructured":"Han Z, Cheng S, Dai D, Kou Y, Zhang X, Li F, et al. The gut microbiome affects response of treatments in HER2-negative advanced gastric cancer. Clin Transl Med. 2023;13(7):e1312.","journal-title":"Clin Transl Med"},{"issue":"3","key":"4551_CR28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/gutjnl-2020-323426","volume":"71","author":"W Si","year":"2022","unstructured":"Si W, Liang H, Bugno J, Xu Q, Ding X, Yang K, et al. Lactobacillus rhamnosus GG induces cGAS\/STING- dependent type I interferon and improves response to immune checkpoint blockade. Gut. 2022;71(3):521\u201333.","journal-title":"Gut"},{"issue":"1","key":"4551_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41698-025-00960-3","volume":"9","author":"R Huo","year":"2025","unstructured":"Huo R, Xu QG, You YQ, Chen YL, Su GJ, Yang KR, et al. Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma. NPJ Precis Oncol. 2025;9(1):251.","journal-title":"NPJ Precis Oncol"},{"issue":"11","key":"4551_CR30","doi-asserted-by":"publisher","first-page":"3147","DOI":"10.1002\/ijc.32920","volume":"146","author":"A Lopes","year":"2020","unstructured":"Lopes A, Billard E, Casse AH, Villeger R, Veziant J, Roche G, et al. Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer. Int J Cancer. 2020;146(11):3147\u201359.","journal-title":"Int J Cancer"},{"issue":"1","key":"4551_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/imt2.156","volume":"3","author":"J Xie","year":"2024","unstructured":"Xie J, Liu M, Deng X, Tang Y, Zheng S, Ou X, et al. Gut microbiota reshapes cancer immunotherapy efficacy: mechanisms and therapeutic strategies. Imeta. 2024;3(1):e156.","journal-title":"Imeta"},{"key":"4551_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128774","volume":"14","author":"H Yuan","year":"2023","unstructured":"Yuan H, Gui R, Wang Z, Fang F, Zhao H. Gut microbiota: a novel and potential target for radioimmunotherapy in colorectal cancer. Front Immunol. 2023;14:1128774.","journal-title":"Front Immunol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04551-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04551-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04551-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T17:57:55Z","timestamp":1790359075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-026-04551-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,25]]},"references-count":32,"alternative-id":["4551"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04551-x","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,25]]},"assertion":[{"value":"26 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflicts of interest to declare.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.\u00a0All subjects were approved by The 900th Hospital of Joint Logistics Support Force of the People\u2019s Liberation Army of China (Approval No.2023XKZL03).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from each subject.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}